Journal Article


Richard J O'Kennedy
Pauline M Rudd
Radka Saldova
Paul J Conroy
Sarah Gilgunn



psa new generation rapid methods predictor glycosylation early detection prostate cancer sweet

Aberrant PSA glycosylation-a sweet predictor of prostate cancer. (2012)

Abstract Prostate cancer-the most commonly diagnosed cancer in men worldwide-can have a substantial effect on quality of life, regardless of the route the cancer takes. The serum PSA assay is the current gold standard option for diagnosing prostate cancer. However, a growing body of evidence suggests that PSA screening for prostate cancer results in extensive overdiagnosis and overtreatment. It is increasingly evident that the potential harm from overdiagnosis (in terms of unnecessary biopsies) must be weighed against the benefit derived from the early detection and treatment of potentially fatal prostate cancers. Rapid screening methods have been used to analyse glycosylation patterns on glycoproteins in large cohorts of patients, enabling the identification of a new generation of disease biomarkers. Changes to the expression status of certain glycan structures are now widely thought to be common features of tumour progression. In light of this development, much research has focused on the potential role of altered PSA glycosylation patterns in discriminating between significant and insignificant prostate cancers, with the aim of developing a more reliable diagnostic tool than the current serum PSA test.
Collections Ireland -> Dublin City University -> PubMed

Full list of authors on original publication

Richard J O'Kennedy, Pauline M Rudd, Radka Saldova, Paul J Conroy, Sarah Gilgunn

Experts in our system

R O'Kennedy
Dublin City University
Total Publications: 197
Pauline M Rudd
University College Dublin
Total Publications: 43
Radka Saldova
University College Dublin
Total Publications: 13
Paul J Conroy
Dublin City University
Total Publications: 9